Clinical Trial Detail

NCT ID NCT03645928
Title Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Iovance Biotherapeutics, Inc.
Indications

melanoma

lung non-small cell carcinoma

head and neck squamous cell carcinoma

Therapies

LN-144 + Pembrolizumab

LN-145

LN-145 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.